{"title":"进行性肺纤维化的结果和进展预测因素。","authors":"Zekai Cen, Tiantian Cen, Qunli Ding, Yun Zhang, Pan Tang, Chengna Lv, Tingting Wu","doi":"10.1080/07853890.2024.2406439","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Progressive pulmonary fibrosis (PPF) is a general term for a class of interstitial lung diseases (ILDs) characterized by a progressive fibrosing (PF) phenotype. Patients with PPF have decreased lung function, exercise ability, and quality of life. The purpose of this study was to investigate the clinical characteristics, potential associated factors for disease progression, and survival outcomes of patients in the PPF population.</p><p><strong>Methods: </strong>This study retrospectively reviewed the data of patients diagnosed with ILD between January 2011 and December 2022 at The First Affiliated Hospital of Ningbo University. A PF phenotype was defined based on the criteria that were used in the PPF clinical practice guidelines, which led to the identification of 92 patients with a PF phenotype among the 177 patients with fibrotic ILD. Baseline clinical information and laboratory parameters were collected and analysed in our cohort.</p><p><strong>Results: </strong>Patients in the PPF group had higher tumour marker levels and lower pulmonary function test results at baseline than did those in the non-PPF group. According to the multivariate logistic regression analysis, age >65 years (OR 2.71, 95% CI 1.26-5.89; <i>p</i> = 0.011), LDH >245 U/L (OR 3.07, 95% CI 1.39-6.78; <i>p</i> = 0.006), CA-153 > 35 U/mL (OR 3.16, 95% CI 1.25-7.97; <i>p</i> = 0.015), FVC <60% predicted (OR 4.82, 95% CI 1.60-14.51; <i>p</i> = 0.005), DLCO <50% predicted (OR 3.21, 95% CI 1.43-7.21; <i>p</i> = 0.005), and the UIP-like pattern on chest HRCT (OR 3.65, 95% CI 1.33-10.07; <i>p</i> = 0.012) were potentially associated with the progression of fibrotic interstitial lung diseases (f-ILDs) to PPF. Furthermore, the PPF group had a poorer survival rate than the non-PPF group (<i>p</i> = 0.0045). According to the multivariate Cox regression analysis, an SPAP ≥ 37 mmHg (HR 2.33, 95% CI 1.09-5.00; <i>p</i> = 0.030) and acute exacerbation (HR 2.88, 95% CI 1.26-6.59; <i>p</i> = 0.012) were identified as significant prognostic factors for mortality in patients with PPFs.</p><p><strong>Conclusions: </strong>Patients who were older, had high CA-153 and LDH levels, had poor pulmonary function test results, or had a UIP-like pattern on chest HRCT were more likely to have indications for the progression of f-ILD to PPF. Increased SPAP and AE are independent risk factors for the prognosis of PPF patients, so additional attention should be given to such patients.</p>","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"56 1","pages":"2406439"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421158/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes and predictors of progression in progressive pulmonary fibrosis.\",\"authors\":\"Zekai Cen, Tiantian Cen, Qunli Ding, Yun Zhang, Pan Tang, Chengna Lv, Tingting Wu\",\"doi\":\"10.1080/07853890.2024.2406439\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Progressive pulmonary fibrosis (PPF) is a general term for a class of interstitial lung diseases (ILDs) characterized by a progressive fibrosing (PF) phenotype. Patients with PPF have decreased lung function, exercise ability, and quality of life. The purpose of this study was to investigate the clinical characteristics, potential associated factors for disease progression, and survival outcomes of patients in the PPF population.</p><p><strong>Methods: </strong>This study retrospectively reviewed the data of patients diagnosed with ILD between January 2011 and December 2022 at The First Affiliated Hospital of Ningbo University. A PF phenotype was defined based on the criteria that were used in the PPF clinical practice guidelines, which led to the identification of 92 patients with a PF phenotype among the 177 patients with fibrotic ILD. Baseline clinical information and laboratory parameters were collected and analysed in our cohort.</p><p><strong>Results: </strong>Patients in the PPF group had higher tumour marker levels and lower pulmonary function test results at baseline than did those in the non-PPF group. According to the multivariate logistic regression analysis, age >65 years (OR 2.71, 95% CI 1.26-5.89; <i>p</i> = 0.011), LDH >245 U/L (OR 3.07, 95% CI 1.39-6.78; <i>p</i> = 0.006), CA-153 > 35 U/mL (OR 3.16, 95% CI 1.25-7.97; <i>p</i> = 0.015), FVC <60% predicted (OR 4.82, 95% CI 1.60-14.51; <i>p</i> = 0.005), DLCO <50% predicted (OR 3.21, 95% CI 1.43-7.21; <i>p</i> = 0.005), and the UIP-like pattern on chest HRCT (OR 3.65, 95% CI 1.33-10.07; <i>p</i> = 0.012) were potentially associated with the progression of fibrotic interstitial lung diseases (f-ILDs) to PPF. Furthermore, the PPF group had a poorer survival rate than the non-PPF group (<i>p</i> = 0.0045). According to the multivariate Cox regression analysis, an SPAP ≥ 37 mmHg (HR 2.33, 95% CI 1.09-5.00; <i>p</i> = 0.030) and acute exacerbation (HR 2.88, 95% CI 1.26-6.59; <i>p</i> = 0.012) were identified as significant prognostic factors for mortality in patients with PPFs.</p><p><strong>Conclusions: </strong>Patients who were older, had high CA-153 and LDH levels, had poor pulmonary function test results, or had a UIP-like pattern on chest HRCT were more likely to have indications for the progression of f-ILD to PPF. Increased SPAP and AE are independent risk factors for the prognosis of PPF patients, so additional attention should be given to such patients.</p>\",\"PeriodicalId\":93874,\"journal\":{\"name\":\"Annals of medicine\",\"volume\":\"56 1\",\"pages\":\"2406439\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421158/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/07853890.2024.2406439\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/07853890.2024.2406439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:进行性肺纤维化(PPF)是一类以进行性纤维化(PF)表型为特征的间质性肺疾病(ILD)的总称。PPF 患者的肺功能、运动能力和生活质量都会下降。本研究旨在调查 PPF 患者的临床特征、疾病进展的潜在相关因素以及生存结果:本研究回顾性分析了 2011 年 1 月至 2022 年 12 月期间在宁波大学附属第一医院确诊的 ILD 患者数据。根据PPF临床实践指南中使用的标准定义了PF表型,从而在177例纤维化ILD患者中发现了92例PF表型患者。在我们的队列中收集并分析了基线临床信息和实验室参数:结果:与非PPF组相比,PPF组患者的肿瘤标志物水平更高,肺功能测试结果更低。根据多变量逻辑回归分析,年龄 >65 岁(OR 2.71,95% CI 1.26-5.89;P = 0.011)、LDH >245 U/L(OR 3.07,95% CI 1.39-6.78;P = 0.006)、CA-153 >35 U/mL(OR 3.16,95% CI 1.25-7.97;P = 0.015)、FVC p = 0.005)、DLCO p = 0.005)和胸部 HRCT 上的 UIP 样型(OR 3.65,95% CI 1.33-10.07;p = 0.012)与纤维化间质性肺疾病(f-ILDs)进展为 PPF 有潜在关联。此外,PPF 组的生存率比非 PPF 组低(p = 0.0045)。根据多变量 Cox 回归分析,SPAP ≥ 37 mmHg(HR 2.33,95% CI 1.09-5.00;p = 0.030)和急性加重(HR 2.88,95% CI 1.26-6.59;p = 0.012)被认为是 PPF 患者死亡的重要预后因素:年龄较大、CA-153和LDH水平较高、肺功能检查结果较差或胸部HRCT显示UIP样模式的患者更有可能有f-ILD进展为PPF的指征。SPAP 和 AE 的增加是影响 PPF 患者预后的独立危险因素,因此应格外关注这类患者。
Outcomes and predictors of progression in progressive pulmonary fibrosis.
Background: Progressive pulmonary fibrosis (PPF) is a general term for a class of interstitial lung diseases (ILDs) characterized by a progressive fibrosing (PF) phenotype. Patients with PPF have decreased lung function, exercise ability, and quality of life. The purpose of this study was to investigate the clinical characteristics, potential associated factors for disease progression, and survival outcomes of patients in the PPF population.
Methods: This study retrospectively reviewed the data of patients diagnosed with ILD between January 2011 and December 2022 at The First Affiliated Hospital of Ningbo University. A PF phenotype was defined based on the criteria that were used in the PPF clinical practice guidelines, which led to the identification of 92 patients with a PF phenotype among the 177 patients with fibrotic ILD. Baseline clinical information and laboratory parameters were collected and analysed in our cohort.
Results: Patients in the PPF group had higher tumour marker levels and lower pulmonary function test results at baseline than did those in the non-PPF group. According to the multivariate logistic regression analysis, age >65 years (OR 2.71, 95% CI 1.26-5.89; p = 0.011), LDH >245 U/L (OR 3.07, 95% CI 1.39-6.78; p = 0.006), CA-153 > 35 U/mL (OR 3.16, 95% CI 1.25-7.97; p = 0.015), FVC <60% predicted (OR 4.82, 95% CI 1.60-14.51; p = 0.005), DLCO <50% predicted (OR 3.21, 95% CI 1.43-7.21; p = 0.005), and the UIP-like pattern on chest HRCT (OR 3.65, 95% CI 1.33-10.07; p = 0.012) were potentially associated with the progression of fibrotic interstitial lung diseases (f-ILDs) to PPF. Furthermore, the PPF group had a poorer survival rate than the non-PPF group (p = 0.0045). According to the multivariate Cox regression analysis, an SPAP ≥ 37 mmHg (HR 2.33, 95% CI 1.09-5.00; p = 0.030) and acute exacerbation (HR 2.88, 95% CI 1.26-6.59; p = 0.012) were identified as significant prognostic factors for mortality in patients with PPFs.
Conclusions: Patients who were older, had high CA-153 and LDH levels, had poor pulmonary function test results, or had a UIP-like pattern on chest HRCT were more likely to have indications for the progression of f-ILD to PPF. Increased SPAP and AE are independent risk factors for the prognosis of PPF patients, so additional attention should be given to such patients.